OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Showing 8 citing articles:
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐1RA ‐based weight‐loss therapies
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, et al.
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 1
Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, et al.
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 1
Exploring hypertension-linked diseases: a comprehensive review of innovative drug combinations with enhanced therapeutic potential
Bhavesh Thakkar, Hetvi Dadhaniya, Kiran Dudhat
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Bhavesh Thakkar, Hetvi Dadhaniya, Kiran Dudhat
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Josiah Moore, Ndidi Iheme, Nicholas Rebold, et al.
Pharmacy (2025) Vol. 13, Iss. 2, pp. 46-46
Open Access
Diabetic Ketoacidosis and the Use of New Hypoglycemic Groups: Real-World Evidence Utilizing the Food and Drug Administration Adverse Event Reporting System
Hilal Thaibah, Otilia J.F. Banji, David Banji, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 214-214
Open Access
Hilal Thaibah, Otilia J.F. Banji, David Banji, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 214-214
Open Access
Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide
Larissa Dăniluc, Adina Braha, Oana Elena Sandu, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 567-567
Open Access
Larissa Dăniluc, Adina Braha, Oana Elena Sandu, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 567-567
Open Access
Adverse drug reaction patterns of GLP ‐1 receptor agonists approved for obesity treatment: Disproportionality analysis from global pharmacovigilance database
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Overcoming Barriers to Unlock the Therapeutic Potential of Saroglitazar for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Murali Krishna Moka, Deepalaxmi Rathakrishnan, D K Sriram, et al.
Clinical Nutrition (2025) Vol. 49, pp. 52-56
Closed Access
Murali Krishna Moka, Deepalaxmi Rathakrishnan, D K Sriram, et al.
Clinical Nutrition (2025) Vol. 49, pp. 52-56
Closed Access
From bench to bedside: targeting ferroptosis and mitochondrial damage in the treatment of diabetic cardiomyopathy
Bin Liu, Qing Jin, Yi Sun, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Bin Liu, Qing Jin, Yi Sun, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
